Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drugging the Next Undruggable KRAS Allele-Gly12Asp.

Journal of medicinal chemistry - 24 Feb 2022

Zheng Qinheng, Peacock D Matthew, Shokat Kevan M

Abstract excerpt

Since its discovery as the first human oncogene in 1983, the small GTPase KRAS has been a major target of cancer drug discovery. The paper reported in this issue describes a long-awaited small molecule drug candidate of the oncogenic KRAS (G12D) mutant for the treatment of currently incurable pancreatic cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Pancreatic Neoplasms
Share to Alleles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Drug Discovery

Share to Gene Expression Regulation, Neoplastic

Share to KRAS gene

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 35167298
DOI: 10.1021/acs.jmedchem.2c00099

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugging the Next Undruggable KRAS Allele-Gly12Asp.PMID 35167298Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

Progress in targeting RAS with small molecule drugsSemantic proximity Read ↗

RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.Semantic proximity Read ↗

KRAS: From undruggable to a druggable Cancer Target.Semantic proximity Read ↗

Drugging the Undruggable: Advances on RAS Targeting in Cancer.Semantic proximity Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

Drugging RAS: Moving Beyond KRASG12C.Semantic proximity Read ↗

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.